In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €190.00. The company’s shares closed ...

Before that, she spent the better part of two decades at EMD Serono, Merck KGaA’s U.S. pharma subsidiary. Her 18 years there spanned a range of roles across its commercial team, including stints ...

Germany’s Merck KGaA has signed a collaboration with Tencent ... Sanofi see it as a lucrative market for diabetes medicines. German Merck said it plans to combine its scientific expertise ...

Merck KGaA and Pfizer have got the fourth checkpoint ... which the regulator has under priority review in bladder cancer. German Merck and Pfizer are now following in the footsteps of Bristol ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck (MRK) is down -10.8%, or -$10.74 to $89.05. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. Next: Access Our New ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Why Merck (MRK) Stock Is Falling Today What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...